Get the Stockscreener App
30.64
2.05%
-0.64
After Hours:
30.64
Ascentage Pharma Group International Adr stock is traded at $30.64, with a volume of 1,370.
It is down -2.05% in the last 24 hours and down -11.09% over the past month.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
See More
Previous Close:
$31.28
Open:
$30.5
24h Volume:
1,370
Relative Volume:
0.16
Market Cap:
$2.86B
Revenue:
$136.33M
Net Income/Loss:
$-56.34M
P/E Ratio:
-40.83
EPS:
-0.7504
Net Cash Flow:
$-18.87M
1W Performance:
-10.67%
1M Performance:
-11.09%
6M Performance:
+21.97%
1Y Performance:
+0.00%
1-Day Range:
$30.50
$30.64
1-Week Range:
$28.70
$32.71
52-Week Range:
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Name
Ascentage Pharma Group International Adr
Sector
Industry
Phone
-
Address
-
Compare AAPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
30.64 | 2.91B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-25 | Initiated | BTIG Research | Buy |
| Nov-05-25 | Initiated | Piper Sandler | Overweight |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Stock (AAPG) Latest News
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownHere's What Happened - MarketBeat
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Today | Live Chart & News - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 12.2%Should You Sell? - MarketBeat
Ascentage Pharma to Engage Investors at December 2025 Conferences - TipRanks
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks - TipRanks
Free cash flow per share of Ascentage Pharma Group International Unsponsored ADR – SWB:36X0 - TradingView
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 - GlobeNewswire Inc.
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Centurion Acquisition Corp. (NASDAQ:ALFUW) Short Interest Down 57.1% in October - Defense World
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 82.7% in October - MarketBeat
Zymeworks’ Promising FRa ADC Potential: Buy Rating Affirmed by Analyst - TipRanks
Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position - TipRanks
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform - TipRanks
Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5%Here's What Happened - MarketBeat
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV) - The Globe and Mail
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 70.0% in September - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.5%Here's What Happened - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Here's Why Ascentage Pharma Group InternationalUnsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Ascentage Pharma to Engage with Investors at September Conferences - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week High – Should You Buy? - Defense World
Ascentage Pharma to Announce 2025 Interim Results and Corporate Update - The Globe and Mail
Ascentage Pharma to Engage in Evercore China Biotech Summit - TipRanks
Ascentage Pharma Completes Offshore Placement to Boost Global Operations - TipRanks
Ascentage Pharma Group International – Unsponsored ADR’s (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rd - Defense World
McGraw Hill, Inc. Plans $500 Million IPO for July 24th (MH) - Defense World
Gates Industrial (NYSE:GTES) Reaches New 1-Year High After Analyst Upgrade - Defense World
Accelerant Holdings (ARX) to Raise $551 Million in IPO - Defense World
Certara (NASDAQ:CERT) Trading Down 4.8% on Analyst Downgrade - Defense World
Diginex Stock Scheduled to Split on Friday, August 1st (NASDAQ:DGNX) - Defense World
Investors Purchase Large Volume of Call Options on Northern Trust (NASDAQ:NTRS) - Defense World
VerticalScope Holdings Inc. (TSE:FORA) Receives C$10.45 Consensus Price Target from Analysts - Defense World
Ascentage Pharma announces $192.3 million share placement By Investing.com - Investing.com South Africa
Ascentage Pharma announces $192.3 million share placement - Investing.com
Ascentage Pharma Group International Adr Stock (AAPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):